Founder, Skin2Neuron
Stories naming Professor Michael Valenzuela. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
SYNthesis BioVentures' third investor letter reports a roughly A$7.5m first close for Alzheimer's biotech S2N, lists co-investors, and profiles managing director Amir's career across OneVentures, Ceres Capital and other life-sciences roles.
Weekly roundup of four raises: Guzman y Gomez banked $134.5 million at a $1.73 billion valuation, Honey Insurance sealed a $108 million Series A, Skin2Neuron gathered $4 million, and AVESS Energy took $1 million.
Sydney biotech Skin2Neuron raised $4 million from SYNthesis BioVentures to develop a hair-follicle cell therapy for Alzheimer's, while the investor reached the first $20 million close of its $75 million bioscience fund.
Also SmartCompany